Bristol-Myers Squibb reported positive results Monday in a crucial immunotherapy trial, using a combination of the two drugs Opdivo and Yervoy to treat patients with a specific type of non-small cell lung cancer patients.

But previously undisclosed changes made by Bristol to the study, known as Checkmate-227, are raising questions about the validity and strength of the results.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • This isn’t quite true. TMB was added as co-primary endpoint before the study enrollment stopped. PDL is still in trials which is continuing. TMB data on progression free survival showed enough impact it hit endpoint early so the data was released

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy